The impact of place and time on the proportion of late-stage diagnosis: the case of prostate cancer in Florida, 1981-2007.

P. Goovaerts,Hong Xiao

DOI: https://doi.org/10.1016/j.sste.2012.03.001

2012-09-01

Spatial and Spatio-temporal Epidemiology

Abstract:

What problem does this paper attempt to address?

A pathway revisited

Gene Chong

DOI: https://doi.org/10.1038/s41589-024-01724-z

IF: 14.8

2024-08-22

Nature Chemical Biology

Abstract:Defects in protein glycosylation and glycan metabolism lead to congenital disorders of glycosylation (CDGs). A key step in N-glycosylation involves the lipid dolichol, which in its phosphorylated form acts as a carrier of glycans to be transferred onto proteins. Previously, dolichol was thought to be directly synthesized from polyprenol by the enzyme SRD5A3. Wilson et al. have now reported a revision to this pathway, with the discovery of a three-step conversion from polyprenol to dolichol. This conversion involves an additional enzyme, DHRSX, which is also found to be associated with CDGs. The discovery first came from identifying four patients presenting with signs of CDG. Analysis of their serum glycoproteins showed aberrant glycosylation, and whole genome or exome sequencing revealed missense variants of the DHRSX gene. DHRSX was previously annotated as an NADPH-dependent oxidoreductase of unknown function. The mutations identified in the patients mapped to a hydrophobic core near a predicted NADP + binding site in an AlphaFold2 model of DHRSX. Wilson et al. found that DHRSX produced the lipid polyprenal in the presence of polyprenol and NADP + , and SRD5A3 catalyzed the next reaction from polyprenal to dolichal. Interestingly, DHRSX also catalyzed the final reaction from dolichal to dolichol in the presence of NADPH, and both reactions involving DHRSX could occur simultaneously in vivo using NAD + for the first reaction and NADPH for the final step. Deficiency in DHRSX led to the accumulation of polyprenol phosphates, which are poorer substrates compared to dolichol phosphates, disrupting glycosyltransferase activity. This study illustrates how the examination of four patients with CDG revealed the unique dual function of DHRSX in the metabolism of polyprenol to dolichol, critical to the initiation of the N-glycosylation pathway. Original reference: Cell 187 , 3585–3601.e22 (2024)

biochemistry & molecular biology
Dysregulated proteome and N‐glycoproteome in ALG1‐deficient fibroblasts

Rohit Budhraja,Neha Joshi,Silvia Radenkovic,Tamas Kozicz,Eva Morava,Akhilesh Pandey

DOI: https://doi.org/10.1002/pmic.202400012

2024-03-14

PROTEOMICS

Abstract:Asparagine‐linked glycosylation 1 protein is a β‐1,4‐mannosyltransferase, is encoded by the ALG1 gene, which catalyzes the first step of mannosylation in N‐glycosylation. Pathogenic variants in ALG1 cause a rare autosomal recessive disorder termed as ALG1‐CDG. We performed a quantitative proteomics and N‐glycoproteomics study in fibroblasts derived from patients with one homozygous and two compound heterozygous pathogenic variants in ALG1. Several proteins that exhibited significant upregulation included insulin‐like growth factor II and pleckstrin, whereas hyaluronan and proteoglycan link protein 1 was downregulated. These proteins are crucial for cell growth, survival and differentiation. Additionally, we observed a decrease in the expression of mitochondrial proteins and an increase in autophagy‐related proteins, suggesting mitochondrial and cellular stress. N‐glycoproteomics revealed the reduction in high‐mannose and complex/hybrid glycopeptides derived from numerous proteins in patients explaining that defect in ALG1 has broad effects on glycosylation. Further, we detected an increase in several short oligosaccharides, including chitobiose (HexNAc2) trisaccharides (Hex‐HexNAc2) and novel tetrasaccharides (NeuAc‐Hex‐HexNAc2) derived from essential proteins including LAMP1, CD44 and integrin. These changes in glycosylation were observed in all patients irrespective of their gene variants. Overall, our findings not only provide novel molecular insights into understanding ALG1‐CDG but also offer short oligosaccharide‐bearing peptides as potential biomarkers.

biochemistry & molecular biology,biochemical research methods
A complement C4–derived glycopeptide is a biomarker for PMM2-CDG

Kishore Garapati,Rohit Budhraja,Mayank Saraswat,Jinyong Kim,Neha Joshi,Gunveen S. Sachdeva,Anu Jain,Anna N. Ligezka,Silvia Radenkovic,Madan Gopal Ramarajan,Savita Udainiya,Kimiyo Raymond,Miao He,Christina Lam,Austin Larson,Andrew C. Edmondson,Kyriakie Sarafoglou,Nicholas B. Larson,Hudson H. Freeze,Matthew J. Schultz,Tamas Kozicz,Eva Morava,Akhilesh Pandey

DOI: https://doi.org/10.1172/jci.insight.172509

IF: 9.4958

2024-04-09

JCI Insight

Abstract:BACKGROUND. Diagnosis of PMM2-CDG, the most common congenital disorder of glycosylation (CDG), relies on measuring carbohydrate-deficient transferrin (CDT) and genetic testing. CDT tests have false negatives and may normalize with age. Site-specific changes in protein N-glycosylation have not been reported in sera in PMM2-CDG. METHODS. Using multistep mass spectrometry–based N-glycoproteomics, we analyzed sera from 72 individuals to discover and validate glycopeptide alterations. We performed comprehensive tandem mass tag–based discovery experiments in well-characterized patients and controls. Next, we developed a method for rapid profiling of additional samples. Finally, targeted mass spectrometry was used for validation in an independent set of samples in a blinded fashion. RESULTS. Of the 3,342 N-glycopeptides identified, patients exhibited decrease in complex-type N-glycans and increase in truncated, mannose-rich, and hybrid species. We identified a glycopeptide from complement C4 carrying the glycan Man 5 GlcNAc 2 , which was not detected in controls, in 5 patients with normal CDT results, including 1 after liver transplant and 2 with a known genetic variant associated with mild disease, indicating greater sensitivity than CDT. It was detected by targeted analysis in 2 individuals with variants of uncertain significance in PMM2 . CONCLUSION. Complement C4–derived Man 5 GlcNAc 2 glycopeptide could be a biomarker for accurate diagnosis and therapeutic monitoring of patients with PMM2-CDG and other CDGs. FUNDING. U54NS115198 (Frontiers in Congenital Disorders of Glycosylation: NINDS; NCATS; Eunice Kennedy Shriver NICHD; Rare Disorders Consortium Disease Network); K08NS118119 (NINDS); Minnesota Partnership for Biotechnology and Medical Genomics; Rocket Fund; R01DK099551 (NIDDK); Mayo Clinic DERIVE Office; Mayo Clinic Center for Biomedical Discovery; IA/CRC/20/1/600002 (Center for Rare Disease Diagnosis, Research and Training; DBT/Wellcome Trust India Alliance)

medicine, research & experimental
(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

Andrew C Edmondson

DOI: https://doi.org/10.1093/glycob/cwae070

2024-09-10

Glycobiology

Abstract:Congenital disorders of glycosylation (CDG) are a group of rare monogenic human disorders caused by defects in the genes encoding the proteins that generate, attach, and modify glycans, thus disrupting cellular glycosylation machinery. Over 200 CDG caused by disruptions of 189 different genes are currently known. The multi-system disease manifestations of the CDG disorders highlight the importance of glycosylation across the organ systems. Clinical manifestations of CDG tend to group among genes contributing to the same glycosylation pathways, suggesting shared pathophysiology related to the glycosylation disruptions. However, the underlying glycosylation disruptions and pathophysiologic mechanisms responsible for specific CDG clinical manifestations have been determined for only a few hypoglycosylated proteins. The Frontiers in CDG Consortium (FCDGC) is an international network of clinical sites, laboratories, and patient advocacy groups established in 2019 to improve clinical symptoms, quality of life, and life expectancy for individuals with CDG. FCDGC seeks to answer decades of unresolved questions, address knowledge gaps, develop and validate new biochemical diagnostic techniques and therapeutic biomarkers, and explore novel therapeutic options for CDG. Over the past 5 years, FCDGC has launched a Natural History Study with over 300 CDG patients, discovered novel biomarkers suggesting new mechanisms of disease, and launched clinical trials aiming to restore appropriate glycosylation and targeting newly identified potential mechanisms of disease. Technical advances in glycobiology are making it increasingly possible to comprehensively catalog glycoproteomic data and to probe functional impact of altered glycosylation. My laboratory applies glycoproteomic technologies to samples from human subjects and genetic model systems to identify glycosylation abnormalities and unlock new insights from translational glycobiology. Current findings and accomplishments highlight the ongoing bottlenecks and knowledge gaps at intersections of glycobiology and clinical care requiring further investigation.
Targeted Proteomics Reveals Quantitative Differences in Low-Abundance Glycosyltransferases of Patients with Congenital Disorders of Glycosylation

Roman Sakson,Lars Beedgen,Patrick Bernhard,K. Merve Alp,Nicole Lübbehusen,Ralph Röth,Beate Niesler,Marcin Luzarowski,Olga Shevchuk,Matthias P. Mayer,Christian Thiel,Thomas Ruppert

DOI: https://doi.org/10.3390/ijms25021191

IF: 5.6

2024-01-18

International Journal of Molecular Sciences

Abstract:Protein glycosylation is an essential post-translational modification in all domains of life. Its impairment in humans can result in severe diseases named congenital disorders of glycosylation (CDGs). Most of the glycosyltransferases (GTs) responsible for proper glycosylation are polytopic membrane proteins that represent challenging targets in proteomics. We established a multiple reaction monitoring (MRM) assay to comprehensively quantify GTs involved in the processes of N-glycosylation and O- and C-mannosylation in the endoplasmic reticulum. High robustness was achieved by using an enriched membrane protein fraction of isotopically labeled HEK 293T cells as an internal protein standard. The analysis of primary skin fibroblasts from eight CDG type I patients with impaired ALG1, ALG2, and ALG11 genes, respectively, revealed a substantial reduction in the corresponding protein levels. The abundance of the other GTs, however, remained unchanged at the transcript and protein levels, indicating that there is no fail-safe mechanism for the early steps of glycosylation in the endoplasmic reticulum. The established MRM assay was shared with the scientific community via the commonly used open source Skyline software environment, including Skyline Batch for automated data analysis. We demonstrate that another research group could easily reproduce all analysis steps, even while using different LC-MS hardware.

biochemistry & molecular biology,chemistry, multidisciplinary
Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

Christina Lam,Carlos Ferreira,Donna Krasnewich,Camilo Toro,Lea Latham,Wadih M. Zein,Tanya Lehky,Carmen Brewer,Eva H. Baker,Audrey Thurm,Cristan A. Farmer,Sergio D. Rosenzweig,Jonathan J. Lyons,John M. Schreiber,Andrea Gropman,Shilpa Lingala,Marc G. Ghany,Beth Solomon,Ellen Macnamara,Mariska Davids,Constantine A. Stratakis,Virginia Kimonis,William A. Gahl,Lynne Wolfe

DOI: https://doi.org/10.1038/gim.2016.75

IF: 8.864

2017-02-01

Genetics in Medicine

Abstract:Purpose:The cytosolic enzyme N-glycanase 1, encoded by NGLY1, catalyzes cleavage of the β-aspartyl glycosylamine bond of N-linked glycoproteins, releasing intact N-glycans from proteins bound for degradation. In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG).Methods:Prospective natural history protocol.Results:In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone dystrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel laboratory findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.Conclusion:Our prospective phenotyping expands the clinical spectrum of NGLY1-CDDG, offers prognostic information, and provides baseline data for evaluating therapeutic interventions.Genet Med19 2, 160–168.

genetics & heredity
A Case of Congenital Disorder of Glycosylation Due to SSR4 Gene Deletion

Lingwei Weng,Qingqing Deng,Xiuli Chen,Kai Wang,Jie Shao

DOI: https://doi.org/10.3760/cma.j.cn511374-20210918-00762

2023-01-01

Abstract:Objective:To explore the clinical and molecular characteristics of a child with Congenital disorders of glycosylation (CDG).Methods:A 4-month-old boy who had presented at the Children's Hospital Affiliated to Zhejiang University Medical School on December 31, 2019 due to feeding difficulties after birth was selected as the study subject. High-throughput sequencing was carried out for the patient, and real-time qPCR was used for validating the suspected deletion fragments and the carrier status of other members of his family.Results:High-throughput sequencing revealed that the child had lost the capture signal for chrX: 153 045 645-153 095 809 (approximately 50 kb), which has involved 4 OMIM genes including SRPK3, IDH3G, SSR4 and PDZD4. qPCR verified that the copy number in this region was zero, while that of his elder brother and parents was all normal. Conclusion:The deletion of the fragment containing the SSR4 gene in the Xq28 region probably underlay the SSR4-CDG in this child.
A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity

S. Sabry,S. Vuillaumier-Barrot,E. Mintet,M. Fasseu,V. Valayannopoulos,D. Héron,N. Dorison,C. Mignot,N. Seta,I. Chantret,T. Dupré,S. E. H. Moore

DOI: https://doi.org/10.1186/s13023-016-0468-1

2016-06-24

Orphanet Journal of Rare Diseases

Abstract:BackgroundType I congenital disorders of glycosylation (CDG-I) are mostly complex multisystemic diseases associated with hypoglycosylated serum glycoproteins. A subgroup harbour mutations in genes necessary for the biosynthesis of the dolichol-linked oligosaccharide (DLO) precursor that is essential for protein N-glycosylation. Here, our objective was to identify the molecular origins of disease in such a CDG-Ix patient presenting with axial hypotonia, peripheral hypertonia, enlarged liver, micropenis, cryptorchidism and sensorineural deafness associated with hypo glycosylated serum glycoproteins.ResultsTargeted sequencing of DNA revealed a splice site mutation in intron 5 and a non-sense mutation in exon 4 of the dehydrodolichol diphosphate synthase gene (DHDDS). Skin biopsy fibroblasts derived from the patient revealed ~20 % residual DHDDS mRNA, ~35 % residual DHDDS activity, reduced dolichol-phosphate, truncated DLO and N-glycans, and an increased ratio of [2-3H]mannose labeled glycoprotein to [2-3H]mannose labeled DLO. Predicted truncated DHDDS transcripts did not complement rer2-deficient yeast. SiRNA-mediated down-regulation of DHDDS in human hepatocellular carcinoma HepG2 cells largely mirrored the biochemical phenotype of cells from the patient. The patient also harboured the homozygous ALG6(F304S) variant, which does not cause CDG but has been reported to be more frequent in PMM2-CDG patients with severe/fatal disease than in those with moderate presentations. WES did not reveal other strong candidate causal genes.ConclusionsWe describe a patient presenting with severe multisystem disease associated with DHDDS deficiency. As retinitis pigmentosa is the only clinical sign in previously reported cases, this report broadens the spectrum of phenotypes associated with this condition.

genetics & heredity,medicine, research & experimental
Expanding the phenotype and metabolic basis of ATP6AP2-congenital disorder of glycosylation in a Chinese patient with a novel variant c.185G>A (p.Gly62Glu)

Yuan Fang,Yi-Zhen Wang,Lian Chen,Xin-Bao Xie

DOI: https://doi.org/10.3389/fgene.2023.1264237

IF: 3.7

2023-11-22

Frontiers in Genetics

Abstract:Background: A rare X-linked hereditary condition known as ATP6AP2-congenital disorder of glycosylation (ATP6AP2-CDG) is caused by pathogenic variants in ATP6AP2 , resulting in autophagic misregulation with reduced siganling of mammalian target of rapamycin (mTOR) that clinically presents with aberrant protein glycosylation, hepatosteatosis, immunodeficiency, cutis laxa, and psychomotor dysfunction. To date, only two missense mutations have been reported in three patients from two unrelated families. Methods: In order to extend the profiles of phenotype and genotype associated with ATP6AP2-CDG, we assessed the clinical history, whole exome sequencing (WES), and liver histology as well as immunohistochemistry in a Chinese patient, and performed quantitative real-time polymerase chain reaction (qRT-PCR), Western blotting and untargeted metabolomics in genetic exogenously constructed cells. Results: The 11-month-old Chinese boy presented with recurrent jaundice, cutis laxa, cirrhosis, growth retardation, coagulopathy, anemia, and cardiomegaly, and underwent liver transplantation. A novel mutation, c.185G>A (p.Gly62Glu), was identified in exon 3 of ATP6AP2 . The expression of ATP6AP2 was observed to remain unchanged in the liver sample of the patient as well as in HEK293T cells harboring the p.Gly62Glu. This missense mutation was found to dysregulate autophagy and mTOR signaling. Moreover, metabolomics analysis revealed that the exogenously introduced Gly62Glu mutant resulted in the downregulation of numerous metabolites involved in lipid metabolism pathway. Conclusion: This study may enable a more detailed exploration of its precise pathogenesis and potential therapeutic interventions.

genetics & heredity
A novel SSR4 variant associated with congenital disorder of glycosylation: a case report and related analysis

Wenqiang Sun,Xinyun Jin,Xueping Zhu

DOI: https://doi.org/10.3389/fgene.2024.1402883

2024-07-17

Abstract:Introduction: Congenital disorders of glycosylation (CDG) refer to monogenetic diseases characterized by defective glycosylation of proteins or lipids causing multi-organ disorders. Here, we investigate the clinical features and genetic variants of SSR4-CDG and conduct a preliminary investigation of its pathogenesis. Methods: We retrospectively report the clinical data of a male infant with early life respiratory distress, congenital diaphragmatic eventration, cosmetic deformities, and moderate growth retardation. Peripheral blood was collected from the case and parents, genomic DNA was extracted and whole-exome sequencing was performed. The mRNA expression of SSR4 gene was quantified by Real-time Quantitative PCR. RNA sequencing analysis was subsequently performed on the case and a healthy child. Results: Whole-exome sequencing of the case and his parents' genomic DNA identified a hemizygous c.80_96del in SSR4, combined with the case's clinical features, the diagnosis of CDG was finally considered. In this case, the expression of SSR4 was downregulated. The case were present with 1,078 genes downregulated and 536 genes upregulated. SSR4 gene expression was significantly downregulated in the case. Meanwhile, gene set enrichment analysis (GSEA) revealed that SSR4-CDG may affect hemostasis, coagulation, catabolism, erythrocyte development and homeostatic regulation, and muscle contraction and regulation, etc. Improvement of growth retardation in case after high calorie formula feeding and rehabilitation training. Conclusion: Our study expanded the SSR4-CDG variant spectrum and clinical phenotype and analyzed pathways potentially affected by SSR4-CDG, which may provide further insights into the function of SSR4 and help clinicians better understand this disorder.
ALG9-CDG: New Clinical Case and Review of the Literature

Kellie Davis,Duncan Webster,Chris Smith,Sheryl Jackson,David Sinasac,Lorne Seargeant,Xing-Chang Wei,Patrick Ferreira,Julian Midgley,Yolanda Foster,Xueli Li,Miao He,Walla Al-Hertani

DOI: https://doi.org/10.1016/j.ymgmr.2017.08.004

IF: 2.082

2017-01-01

Molecular Genetics and Metabolism Reports

Abstract:Congenital disorders of glycosylation (CDG) are a group of metabolic diseases resulting from defects in glycan synthesis or processing. The number of subgroups and their phenotypic spectrums continue to expand with most related to deficiencies of N-glycosylation. ALG9-CDG (previously CDG-IL) is the result of a mutation in ALG9. This gene encodes the enzyme alpha-1,2-mannosyltransferase. To date, a total of 10 patients from 6 different families have been reported with one of four ALG9 mutations. Seven of these patients had a similar phenotype with failure to thrive, dysmorphic features, seizures, hepatic and/or renal cysts; the other three patients died in utero from a lethal skeletal dysplasia. This report describes an additional patient with ALG9-CDG who has a milder phenotype. This patient is a term female born to Caucasian, Canadian, non-consanguineous parents of Scottish decent. Prenatally, dysmorphic features, numerous renal cysts and minor cardiac malformations were detected. Post-natally, dysmorphic features included shallow orbits, micrognathia, hypoplastic nipples, talipes equinovarus, lipodystrophy and cutis marmorata. She developed failure to thrive and seizures. The metabolic work-up included analysis of a transferrin isoelectric focusing, which showed a type 1 pattern. This was confirmed by glycan profiling, which identified ahomozygous mutation in ALG9, c.860A > G (p.Tyr287Cys) (NM_1234567890). This had been previously published as a pathogenic mutation in two Canadian patients. Our goal is to contribute to the growing body of knowledge for this disorder by describing the phenotypic spectrum and providing further insight on prognosis.
Deficient glycan extension and endoplasmic reticulum stresses in ALG3‐CDG

Earnest J. P. Daniel,Andrew C. Edmondson,Yair Argon,Hind Alsharhan,Christina Lam,Hudson H. Freeze,Miao He

DOI: https://doi.org/10.1002/jimd.12739

IF: 4.7501

2024-04-12

Journal of Inherited Metabolic Disease

Abstract:ALG3‐CDG is a rare congenital disorder of glycosylation (CDG) with a clinical phenotype that includes neurological manifestations, transaminitis, and frequent infections. The ALG3 enzyme catalyzes the first step of endoplasmic reticulum (ER) luminal glycan extension by adding mannose from Dol‐P‐Man to Dol‐PP‐Man5GlcNAc2 (Man5) forming Dol‐PP‐Man6. Such glycan extension is the first and fastest cellular response to ER stress, which is deficient in ALG3‐CDG. In this study, we provide evidence that the unfolded protein response (UPR) and ER‐associated degradation activities are increased in ALG3‐CDG patient‐derived cultured skin fibroblasts and there is constitutive activation of UPR mediated by the IRE1‐α pathway. In addition, we show that N‐linked Man3‐4 glycans are increased in cellular glycoproteins and secreted plasma glycoproteins with hepatic or non‐hepatic origin. We found that like other CDGs such as ALG1‐ or PMM2‐CDG, in transferrin, the assembling intermediate Man5 in ALG3‐CDG, are likely further processed into a distinct glycan, NeuAc1Gal1GlcNAc1Man3GlcNAc2, probably by Golgi mannosidases and glycosyltransferases. We predict it to be a mono‐antennary glycan with the same molecular weight as the truncated glycan described in MGAT2‐CDG. In summary, this study elucidates multiple previously unrecognized biochemical consequences of the glycan extension deficiency in ALG3‐CDG which will have important implications in the pathogenesis of CDG.

genetics & heredity,endocrinology & metabolism,medicine, research & experimental
Review and metabolomic profiling of unsolved case reveals newly reported autosomal dominant congenital disorder of glycosylation, type Iw formerly thought to only be an autosomal recessive condition

Kimberly M. Ezell,Yutaka Furuta,Devin Oglesbee,Eniko K. Pivnick,David Rinker,Jonathan H. Sheehan,Rory J. Tinker,Rizwan Hamid,Joy D. Cogan,Lynette Rives,Serena Neumann,Brian Corner,Mary Koziura,John A. Phillips

DOI: https://doi.org/10.1016/j.ymgmr.2024.101145

IF: 2.082

2024-10-06

Molecular Genetics and Metabolism Reports

Abstract:Autosomal dominant congenital disorder of glycosylation (CDG) type Iw (OMIM# 619714 ) is caused by a heterozygous mutation in the STT3A gene. Most CDGs have an autosomal recessive (AR) mode of inheritance, but several cases with an autosomal dominant (AD) form of an AR CDG have been recently identified. This report describes a 17-year-old male who was referred to the Undiagnosed Diseases Network (UDN) with a history of macrocephaly, failure to thrive, short stature, epilepsy, autism, attention-deficit/hyperactivity disorder, mild developmental delay, intermittent hypotonia, dysmorphic features, and mildly enlarged aortic root. Trio exome sequencing was negative. His biochemical workup included normal plasma amino acids, ammonia, acylcarnitine profile and urine organic and amino acids. His UDN genome sequencing (GS) identified a previously unreported de novo STT3A variant (c.1631A > G: p.Asn544Ser). This variant removes a glycosylation site and was predicted to be destabilizing by structural biology modeling. The patient was formally diagnosed by the UDN Metabolomics Core as having an abnormal transferrin profile indicative of CDG type Iw through metabolomic profiling. We report here an affected male with phenotypic, molecular, and metabolic findings consistent with CDG type Iw due to a heterozygous STT3A variant. This case highlights the importance of further testing of individuals with the phenotypic and metabolic findings of an AR disorder who are heterozygous for a single disease-causing allele and can be shown to have a new AD form of the disorder that represents clinical heterogeneity.

genetics & heredity
Congenital Disorders of Glycosylation from a Neurological Perspective

Justyna Paprocka,Aleksandra Jezela-Stanek,Anna Tylki-Szymańska,Stephanie Grunewald

DOI: https://doi.org/10.3390/brainsci11010088

IF: 3.333

2021-01-11

Brain Sciences

Abstract:Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post-translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations in the following genes: ALG13, DOLK, DPAGT1, SLC35A2, ST3GAL3, PIGA, PIGW, ST3GAL5. On brain neuroimaging, atrophic changes of the cerebellum and cerebrum are frequently seen. Brain malformations particularly in the group of dystroglycanopathies are reported. Despite the growing number of CDG patients in the world and often neurological symptoms dominating in the clinical picture, the number of performed screening tests eg transferrin isoforms is systematically decreasing as broadened genetic testing is recently more favored. The aim of the review is the summary of selected neurological symptoms in CDG described in the literature in one paper. It is especially important for pediatric neurologists not experienced in the field of metabolic medicine. It may help to facilitate the diagnosis of this expanding group of disorders. Biochemically, this paper focuses on protein glycosylation abnormalities.

neurosciences
24-hour pattern of immunoreactive beta-endorphin and adrenocorticotropic hormone (ACTH) in rat plasma and tissues.

O. Vuolteenaho,J. Leppäluoto

Abstract:The levels of beta-endorphin and adrenocorticotropic hormone (ACTH) were measured by radioimmunoassays in rat plasma, pituitary, hypothalamus and pineal at different times of the day. Significant diurnal variations in the levels of immunoreactive beta-endorphin were detected in the plasma and hypothalamus. Immunoreactive ACTH levels varied significantly during the darklight cycle in the posterior lobe of the pituitary, and in the hypothalamus, but not in the plasma. The hormone levels were high during the dark, except in the posterior pituitary, where the highest levels were detected during the light period. Gel chromatography showed that both beta-endorphin and ACTH immunoreactivities in plasma and tissues consist of multiple components.
Preparation of small unilamellar vesicles (SUV) and biophysical characterization of their complexes with poly‐l‐lysine‐condensed plasmid DNA

Leigh A. Maguire,H. Zhang,P. Shamlou

DOI: https://doi.org/10.1042/BA20020107

2003-02-01

Biotechnology and Applied Biochemistry

Abstract:Liposomes have numerous applications in the (bio)pharmaceutical industries as agents in the synthesis of new biomaterials for use in areas including gene delivery. There is currently a need to establish efficient scaleable methods for the manufacture of liposomes, and in the present paper we describe the operation of a new high‐velocity jet homogenizer for downsizing of multilamellar large vesicles to produce small unilamellar vesicles (SUV). Measurements of size distribution of SUVs are presented and compared with mathematical simulations based on the solution of a population balance equation combined with computational‐fluid‐dynamics analysis of flow in the homogenizer. Anionic SUVs are produced by the new method and incubated with poly‐l‐lysine (PLL)‐condensed plasmid DNA (pDNA) to generate complexes under different physico‐chemical conditions. The colloidal properties of the resulting complexes, including their size and charge, are measured using a Zetasizer and the encapsulation efficiency is obtained experimentally using a Pico Green assay. The results show that between 85 and 95% of the PLL‐pDNA condensed plasmids were encapsulated by the liposomes, the smaller liposomes being more effective in encapsulating the complexes.
Mass spectrometry in the characterization of human genetic N-glycosylation defects

Rita Barone,Luisa Sturiale,Domenico Garozzo

DOI: https://doi.org/10.1002/mas.20201

Abstract:Human genetic diseases that affect N-glycosylation result from the defective synthesis of the N-linked sugar moiety (glycan) of glycoproteins. The role of glycans for proper protein folding and biological functions is illustrated in the variety and severity of clinical manifestations shared by congenital disorders of glycosylation (CDG). This family of inherited metabolic disorders includes defects in the assembly of the oligosaccharide precursor that lead to an under-occupancy of N-glycosylation sites (CDG-I), and defects of glycan remodeling (CDG-II). Mass spectrometry constitutes a key tool for characterization of CDG-I defects by mass resolution of native protein glycoforms that differ for glycosylation-site occupancy. Glycan MS analyses in CDG-II is mandatory to detect whenever possible a repertoire of structures to pinpoint candidate enzymes and genes responsible for the abnormal N-glycan synthesis. In this manuscript, we review the MS applications in the area of CDG and related disorders with a special emphasis on those techniques that have been already applied or might become functional for diagnosis, characterization, and treatment monitoring in some specific conditions.
Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort

Christina Lam,Fernando Scaglia,Gerard T Berry,Austin Larson,Kyriakie Sarafoglou,Hans C Andersson,Evgenia Sklirou,Queenie K G Tan,Rodrigo T Starosta,Mustafa Sadek,Lynne Wolfe,Seishu Horikoshi,May Ali,Rita Barone,Teresa Campbell,Irene J Chang,Kiaira Coles,Edward Cook,Erik A Eklund,Nicole M Engelhardt,Mary Freeman,Jennifer Friedman,Debbie Y T Fu,Grace Botzo,Brandy Rawls,Christien Hernandez,Christin Johnsen,Kierstin Keller,Sara Kramer,Bryce Kuschel,Angela Leshinski,Ivan Martinez-Duncker,Gina L Mazza,Saadet Mercimek-Andrews,Bradley S Miller,Karthik Muthusamy,Juanita Neira,Marc C Patterson,Natalie Pogorelc,Lex N Powers,Elizabeth Ramey,Michaela Reinhart,Audrey Squire,Jenny Thies,Jerry Vockley,Hayden Vreugdenhil,Peter Witters,Mehdi Youbi,Aziza Zeighami,Roni Zemet,Andrew C Edmondson,Eva Morava

DOI: https://doi.org/10.1016/j.ymgme.2024.108509

Abstract:Objective: Our report describes clinical, genetic, and biochemical features of participants with a molecularly confirmed congenital disorder of glycosylation (CDG) enrolled in the Frontiers in Congenital Disorders of Glycosylation (FCDGC) Natural History cohort at year 5 of the study. Methods: We enrolled individuals with a known or suspected CDG into the FCDGC Natural History Study, a multicenter prospective and retrospective natural history study of all genetic causes of CDG. We conducted a cross-sectional analysis of baseline study visit data from participants with confirmed CDG who were consented into the FCDGC Natural History Study (5U54NS115198) from October 2019 to November 2023. Results: Three hundred thirty-three subjects consented to the FCDGC Natural History Study. Of these, 280 unique individuals had genetic data available that was consistent with a diagnosis of CDG. These 280 individuals were enrolled into the study between October 8, 2019 and November 29, 2023. One hundred forty-one (50.4%) were female, and 139 (49.6%) were male. Mean and median age at enrollment was 10.1 and 6.5 years, respectively, with a range of 0.22 to 71.4 years. The cohort encompassed individuals with disorders of N-linked protein glycosylation (57%), glycosylphosphatidylinositol anchor disorder (GPI anchor) (15%), disorders of Golgi homeostasis, trafficking and transport (12%), dolichol metabolism disorders (5%), disorders of multiple pathways (6%), and other (5%). The most frequent presenting symptom(s) leading to diagnosis were developmental delay/disability (77%), followed by hypotonia (56%) and feeding difficulties (42%). Mean and median time between first related symptom and diagnosis was 2.7 and 0.8 years, respectively. One hundred percent of individuals in our cohort had developmental differences/disabilities at the time of their baseline visit, followed by 97% with neurologic involvement, 91% with gastrointestinal (GI)/liver involvement, and 88% with musculoskeletal involvement. Severity of disease in individuals was scored on the Nijmegen Progression CDG Rating Scale (NPCRS) with 27% of scores categorized as mild, 44% moderate, and 29% severe. Of the individuals with N-linked protein glycosylation defects, 83% of those with data showed a type 1 pattern on carbohydrate deficient transferrin (CDT) analysis including 82/84 individuals with PMM2-CDG, 6% a type 2 pattern, 1% both type 1 and type 2 pattern and 10% a normal or nonspecific pattern. One hundred percent of individuals with Golgi homeostasis and trafficking defects with data showed a type 2 pattern on CDT analysis, while Golgi transport defect showed a type II pattern 73% of the time, a type 1 pattern for 7%, and 20% had a normal or nonspecific pattern. Most of the variants documented were classified as pathogenic or likely pathogenic using ACMG criteria. For the majority of the variants, the predicted molecular consequence was missense followed by nonsense and splice site, and the majority of the diagnoses are inherited in an autosomal recessive pattern but with disorders of all major nuclear inheritance included. Discussion: The FCDGC Natural History Study serves as an important resource to build future research studies, improve clinical care, and prepare for clinical trial readiness. Herein is the first overview of CDG participants of the FCDGC Natural History Study.
A pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis

Matthew P Wilson,Takfarinas Kentache,Charlotte R Althoff,Céline Schulz,Geoffroy de Bettignies,Gisèle Mateu Cabrera,Loreta Cimbalistiene,Birute Burnyte,Grace Yoon,Gregory Costain,Sandrine Vuillaumier-Barrot,David Cheillan,Daisy Rymen,Lucie Rychtarova,Hana Hansikova,Marina Bury,Joseph P Dewulf,Francesco Caligiore,Jaak Jaeken,Vincent Cantagrel,Emile Van Schaftingen,Gert Matthijs,François Foulquier,Guido T Bommer

DOI: https://doi.org/10.1016/j.cell.2024.04.041

IF: 64.5

2024-07-11

Cell

Abstract:Dolichol is a lipid critical for N-glycosylation as a carrier for activated sugars and nascent oligosaccharides. It is commonly thought to be directly produced from polyprenol by the enzyme SRD5A3. Instead, we found that dolichol synthesis requires a three-step detour involving additional metabolites, where SRD5A3 catalyzes only the second reaction. The first and third steps are performed by DHRSX, whose gene resides on the pseudoautosomal regions of the X and Y chromosomes. Accordingly, we report a pseudoautosomal-recessive disease presenting as a congenital disorder of glycosylation in patients with missense variants in DHRSX (DHRSX-CDG). Of note, DHRSX has a unique dual substrate and cofactor specificity, allowing it to act as a NAD+-dependent dehydrogenase and as a NADPH-dependent reductase in two non-consecutive steps. Thus, our work reveals unexpected complexity in the terminal steps of dolichol biosynthesis. Furthermore, we provide insights into the mechanism by which dolichol metabolism defects contribute to disease.
A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG

Hans M. Dalton,Naomi J. Young,Alexys R. Berman,Heather D. Evans,Sydney J. Peterson,Kaylee A. Patterson,Clement Y. Chow

DOI: https://doi.org/10.1371/journal.pgen.1011458

IF: 4.5

2024-10-29

PLoS Genetics

Abstract:DPAGT1-CDG is a Congenital Disorder of Glycosylation (CDG) that lacks effective therapies. It is caused by mutations in the gene DPAGT1 which encodes the first enzyme in N-linked glycosylation. We used a Drosophila rough eye model of DPAGT1-CDG with an improperly developed, small eye phenotype. We performed a drug repurposing screen on this model using 1,520 small molecules that are 98% FDA/EMA-approved to find drugs that improved its eye. We identified 42 candidate drugs that improved the DPAGT1-CDG model. Notably from this screen, we found that pharmacological and genetic inhibition of the dopamine D2 receptor partially rescued the DPAGT1-CDG model. Loss of both dopamine synthesis and recycling partially rescued the model, suggesting that dopaminergic flux and subsequent binding to D2 receptors is detrimental under DPAGT1 deficiency. This links dopamine signaling to N-glycosylation and represents a new potential therapeutic target for treating DPAGT1-CDG. We also genetically validate other top drug categories including acetylcholine-related drugs, COX inhibitors, and an inhibitor of NKCC1. These drugs and subsequent analyses reveal novel biology in DPAGT1 mechanisms, and they may represent new therapeutic options for DPAGT1-CDG. Some proteins require the attachment of sugars—like mannose and galactose—in order to perform their function. The process that attaches these sugars is called "glycosylation". Genetic mutations in glycosylation pathways cause Congenital Disorders of Glycosylation ("CDGs"). CDGs are devastating disorders causing a multitude of symptoms, including seizures and developmental delay, and they have few treatment options. We wanted to find new potential treatment options for the CDG called DPAGT1-CDG. We use a model of DPAGT1-CDG that has inhibited glycosylation resulting in impaired eye development. We used a "drug repurposing screen", where we screened 1,520 drugs that are 99% FDA- or EMA-approved, to find drugs that improved its eye. We found 42 drug hits, including classes like dopamine receptor inhibitors, NSAIDs, and antihistamines. We found that the dopamine receptor inhibitors caused the strongest improvement. In addition, genetically impairing multiple parts of the dopamine pathway (e.g. how dopamine is made or recycled) also improved the model. This suggests that dopamine signaling is important in DPAGT1-CDG, and it could represent a new therapeutic option for patients. Overall, we present validation of several of our drugs, and these represent potential new treatments while also improving our understanding of glycosylation.

genetics & heredity

The impact of place and time on the proportion of late-stage diagnosis: the case of prostate cancer in Florida, 1981-2007.

A pathway revisited

Dysregulated proteome and N‐glycoproteome in ALG1‐deficient fibroblasts

A complement C4–derived glycopeptide is a biomarker for PMM2-CDG

(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

Targeted Proteomics Reveals Quantitative Differences in Low-Abundance Glycosyltransferases of Patients with Congenital Disorders of Glycosylation

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

A Case of Congenital Disorder of Glycosylation Due to SSR4 Gene Deletion

A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity

Expanding the phenotype and metabolic basis of ATP6AP2-congenital disorder of glycosylation in a Chinese patient with a novel variant c.185G>A (p.Gly62Glu)

A novel SSR4 variant associated with congenital disorder of glycosylation: a case report and related analysis

ALG9-CDG: New Clinical Case and Review of the Literature

Deficient glycan extension and endoplasmic reticulum stresses in ALG3‐CDG

Review and metabolomic profiling of unsolved case reveals newly reported autosomal dominant congenital disorder of glycosylation, type Iw formerly thought to only be an autosomal recessive condition

Congenital Disorders of Glycosylation from a Neurological Perspective

24-hour pattern of immunoreactive beta-endorphin and adrenocorticotropic hormone (ACTH) in rat plasma and tissues.

Preparation of small unilamellar vesicles (SUV) and biophysical characterization of their complexes with poly‐l‐lysine‐condensed plasmid DNA

Mass spectrometry in the characterization of human genetic N-glycosylation defects

Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort

A pseudoautosomal glycosylation disorder prompts the revision of dolichol biosynthesis

A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG